↓ Skip to main content

Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol

Overview of attention for article published in Pharmacological Reviews, February 2006
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

blogs
2 blogs
twitter
4 X users
patent
14 patents
facebook
2 Facebook pages
wikipedia
19 Wikipedia pages
q&a
1 Q&A thread

Citations

dimensions_citation
955 Dimensions

Readers on

mendeley
461 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol
Published in
Pharmacological Reviews, February 2006
DOI 10.1124/pr.58.1.6
Pubmed ID
Authors

Pál Pacher, Alex Nivorozhkin, Csaba Szabó

Abstract

The prototypical xanthine oxidase (XO) inhibitor allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. More recent data indicate that XO also plays an important role in various forms of ischemic and other types of tissue and vascular injuries, inflammatory diseases, and chronic heart failure. Allopurinol and its active metabolite oxypurinol showed considerable promise in the treatment of these conditions both in experimental animals and in small-scale human clinical trials. Although some of the beneficial effects of these compounds may be unrelated to the inhibition of the XO, the encouraging findings rekindled significant interest in the development of additional, novel series of XO inhibitors for various therapeutic indications. Here we present a critical overview of the effects of XO inhibitors in various pathophysiological conditions and also review the various emerging therapeutic strategies offered by this approach.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 461 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Sweden 2 <1%
Brazil 1 <1%
Canada 1 <1%
United States 1 <1%
Poland 1 <1%
Unknown 455 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 67 15%
Student > Bachelor 62 13%
Researcher 59 13%
Student > Master 52 11%
Student > Doctoral Student 27 6%
Other 78 17%
Unknown 116 25%
Readers by discipline Count As %
Medicine and Dentistry 88 19%
Agricultural and Biological Sciences 76 16%
Biochemistry, Genetics and Molecular Biology 47 10%
Pharmacology, Toxicology and Pharmaceutical Science 43 9%
Chemistry 40 9%
Other 39 8%
Unknown 128 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2022.
All research outputs
#1,229,386
of 24,274,366 outputs
Outputs from Pharmacological Reviews
#59
of 681 outputs
Outputs of similar age
#1,934
of 73,653 outputs
Outputs of similar age from Pharmacological Reviews
#1
of 5 outputs
Altmetric has tracked 24,274,366 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 681 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.6. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 73,653 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them